121 related articles for article (PubMed ID: 31436246)
1. Multiple MicroRNAs synergistically promote tolerance to epidermal growth factor receptor-targeted drugs in smoked lung cancer therapies.
Pan L; Wang H; Jiang C; Li W; Chen Y; Ying G
J Cancer Res Ther; 2019; 15(4):876-881. PubMed ID: 31436246
[TBL] [Abstract][Full Text] [Related]
2. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
3. Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance.
Dai C; Liu B; Li S; Hong Y; Si J; Xiong Y; Wu N; Ma Y
Technol Cancer Res Treat; 2021; 20():15330338211056809. PubMed ID: 34825849
[No Abstract] [Full Text] [Related]
4. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
Kawana S; Saito R; Miki Y; Kimura Y; Abe J; Sato I; Endo M; Sugawara S; Sasano H
Cancer Med; 2021 Jan; 10(2):718-727. PubMed ID: 33305905
[TBL] [Abstract][Full Text] [Related]
5. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
7. Persistence of smoking induced non-small cell lung carcinogenesis by decreasing ERBB pathway-related microRNA expression.
Zhang L; Wang H; Wang C
Thorac Cancer; 2019 Apr; 10(4):890-897. PubMed ID: 30868748
[TBL] [Abstract][Full Text] [Related]
8. Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing.
Hu S; Yuan Y; Song Z; Yan D; Kong X
Cell Physiol Biochem; 2018; 51(6):2509-2522. PubMed ID: 30557872
[TBL] [Abstract][Full Text] [Related]
9. Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.
Zhang W; Zhang Q; Che L; Xie Z; Cai X; Gong L; Li Z; Liu D; Liu S
BMC Cancer; 2022 Mar; 22(1):299. PubMed ID: 35313857
[TBL] [Abstract][Full Text] [Related]
10. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
11. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
12. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
[TBL] [Abstract][Full Text] [Related]
13. Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer.
Qu L; Li L; Zheng X; Fu H; Tang C; Qin H; Li X; Wang H; Li J; Wang W; Yang S; Wang L; Zhao G; Lv P; Lei Y; Zhang M; Gao H; Song S; Liu X
Oncotarget; 2017 Jul; 8(28):45807-45824. PubMed ID: 28496005
[TBL] [Abstract][Full Text] [Related]
14. Analysis of microRNA (miRNA) expression profiles reveals 11 key biomarkers associated with non-small cell lung cancer.
Wang K; Chen M; Wu W
World J Surg Oncol; 2017 Sep; 15(1):175. PubMed ID: 28927412
[TBL] [Abstract][Full Text] [Related]
15. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
16. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
17. Microarray data analysis on gene and miRNA expression to identify biomarkers in non-small cell lung cancer.
Jin X; Guan Y; Zhang Z; Wang H
BMC Cancer; 2020 Apr; 20(1):329. PubMed ID: 32299382
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT
Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579
[TBL] [Abstract][Full Text] [Related]
19. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation.
Cho WC; Chow AS; Au JS
Eur J Cancer; 2009 Aug; 45(12):2197-206. PubMed ID: 19493678
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
